Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rVSVN4CT1-EBOVGP1 in healthy adults
NCT02718469Phase 1Completed
- Sponsor
- Auro Vaccines
- Start
- Dec 2015
- Primary completion
- Sep 2016
- Modality
- Oncolytic Viruses, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rVSVN4CT1-EBOVGP1 in Ebola virus disease (EVD) (4 arms), sponsored by Auro Vaccines. Primary endpoint: Incidence of Treatment Emergent Adverse Events at 9 months. Started Dec 2015; status: completed.
02
Drugs
rVSVN4CT1-EBOVGP1
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT02718469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02718469.